Table II.
Clinical characteristics of patients with breast cancer.
| Group II ‘non metastatic’ | Group III ‘metastatic’ | |||||
|---|---|---|---|---|---|---|
| Patient characteristics | No. | % | No. | % | χ2 test | P-value |
| Menopausal status | 2.36 | 0.2140 | ||||
| Premenopausal | 21 | 42.0 | 24 | 48.0 | ||
| Postmenopausal | 29 | 58.0 | 26 | 52.0 | ||
| Pathology | 2.08 | 0.1060 | ||||
| Infiltrating ductal carcinoma | 44 | 88.0 | 48 | 96.0 | ||
| Infiltratin globular carcinoma | 6 | 12.0 | 2 | 4.0 | ||
| HER2 | 4.083 | 0.0433a | ||||
| Positive | 30 | 60.0 | 37 | 74.0 | ||
| Negative | 20 | 40.0 | 13 | 26.0 | ||
| PR | 4.504 | 0.0330a | ||||
| Positive | 16 | 32.0 | 9 | 18.0 | ||
| Negative | 34 | 68.0 | 41 | 82.0 | ||
| ER | 0.000 | >0.9999 | ||||
| Positive | 10 | 20.0 | 10 | 20.0 | ||
| Negative | 40 | 80.0 | 40 | 80.0 | ||
| Lymphovascular invasion | 13.2 | 0.0010a | ||||
| Positive | 12 | 24.0 | 23 | 46.0 | ||
| Negative | 38 | 76.0 | 27 | 54.0 | ||
| T stage | 173.1 | 0.0010a | ||||
| I | 2 | 4.0 | 20 | 40.0 | ||
| II | 27 | 54.0 | 24 | 48.0 | ||
| III | 19 | 38.0 | 5 | 10.0 | ||
| IV | 2 | 4.0 | 1 | 2.0 | ||
| N stage | 297.5 | 0.0010a | ||||
| 0 | 1 | 2.0 | 18 | 36.0 | ||
| 1 | 11 | 22.0 | 9 | 18.0 | ||
| 2 | 24 | 48.0 | 19 | 38.0 | ||
| 3 | 14 | 28.0 | 4 | 8.0 | ||
| M stage | 25.6 | 0.0001a | ||||
| Positive | 0 | 0.0 | 50 | 100.0 | ||
| Negative | 50.0 | 100.0 | 0 | 0.0 | ||
| Grade | 36.2 | 0.0001a | ||||
| I | 38 | 76.0 | 3 | 6.0 | ||
| II | 11 | 22.0 | 44 | 88.0 | ||
| III | 1 | 2.0 | 3 | 6.0 | ||
| Presentation | 504.417 | 0.001a | ||||
| Breast lump | 38 | 76.0 | 0 | 0.0 | ||
| Nipple retraction | 4 | 8.0 | 47 | 94.0 | ||
| Inflammed swollen breast | 1 | 2.0 | 1 | 2.0 | ||
| Nipple and areola ulcer | 1 | 2.0 | 1 | 2.0 | ||
| Nipple discharge | 6 | 12.0 | 1 | 2.0 | ||
aP<0.05. P1, comparison between the control and non-metastatic groups; P2, comparison between the control and metastatic groups; P3, comparison between the metastatic and non-metastatic groups. T, tumor size; ER, estrogen receptor; N, lymph node status; PR, progesterone receptor; M, metastatic status; HER2, human epidermal growth factor receptor 2.